An international multi-centre prospective study on the efficacy of an intraarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 months follow-up

Acta Veterinaria Scandinavica

Aziz Tnibar⁶  Hans Schougaard⁴  Linus Camitz¹  Jonas Rasmussen⁵  Marc Koene²  Werner Jahn³  Bo Markussen⁷ 

[1] Camitz equestrian, Aasoe Mosevej 13, Glumsoe, DK-4171, Denmark

[2] Tieraerztlische Klinik fuer Pferde, Essener Strasse 39a, Bakum, D-49456, Germany

[3] Pferdeklinik Bargteheide, Alte Landstrasse 104, Bargteheide, D-22941, Germany

[4] Noerlund Hestehospital, Roedebækvej 2, Them, DK-8653, Denmark

[5] Hoejgaard Hestehospital, Rugaardsvej 696, Morud, DK-5462, Denmark

[6] Department of Large Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Hoejbakkegaard alle 5, Taastrup, DK-2630, Denmark

[7] Department of Mathematical Sciences, Laboratory of Applied Statistics, University of Copenhagen, Universitetsparken 5, Copenhagen, DK-2100, Denmark

关键词: years follow-up;    2 ;    Polyacrylamide hydrogel;    Treatment;    Horse;    Osteoarthritis;   

Others  :  1173886
DOI  :  10.1186/s13028-015-0110-6

 received in 2014-11-17, accepted in 2015-04-09,  发布年份 2015

【 摘 要 】

Background

Polyacrylamide hydrogel (PAAG) was evaluated recently to treat osteoarthritis (OA) in horses with highly encouraging results; however no long term field-study was done to explore its clinical efficacy and lasting effect. The objective of this study was to evaluate the efficacy of PAAG in improving clinical signs of OA in horses. We hypothesized that lameness grade would significantly improve and the effect would last at least 2 years in osteoarthritic joints treated with PAAG. Forty three horses older than 2 years with OA in only one joint based on clinical evaluation, intra-articular anaesthesia and imaging (radiography) were included in this study. Horses were injected with 2 ml of PAAG into the affected joint and were followed up at 1, 3, 6, 12 and 24 months. Efficacy of PAAG was evaluated by blinded clinical assessment of lameness. Adverse reactions to joint injection were assessed. Data relating to case details, type of activity, joint and limb involved, lameness duration, lameness grading, previous joint treatment, joint effusion grading, radiographic grading, and owner assessment were recorded. Factors associated with the outcome measure “lameness grading” were analyzed using generalized linear mixed model for logistic regression.

Results

At 1, 3, 6, 12 and 24 months follow-up, 59%, 69%, 79%, 81/% and 82.5% of horses were non-lame respectively. Reduction of joint effusion was observed over time. No side effect was observed in the treated joints. There was a significant decrease in lameness grade from baseline to 1, 3, 6, 12 and 24 months (P < 0.0001) and a significant positive association with joint effusion (P < 0.0001). Estimates for odds ratio (OR) showed that the effect of treatment increased over time (OR for lower lameness from month 1 to month 24 relative to baseline increased from 20 to 58).

Conclusions

PAAG significantly alleviated lameness and joint effusion in osteoarthritic joints. PAAG is a safe and lasting (at least 24 months) OA treatment in horses. PAAG is a promising new treatment for OA in horses.

【 授权许可】

   
2015 Tnibar et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]United States Department of Agriculture. Lameness and laminitis in US horses. National Animal Health Monitoring System, 2000 [http://www.aphis.usda.gov/animal_health/nahms/equine/downloads/equine98/Equine98_dr_Lame.pdf]
• [2]Caron JP. Osteoarthritis. In: Diagnosis and Management of Lameness in the Horse. 2nd ed. Ross MW, Dyson SJ, editors. Elsevier, Saunders, St Louis; 2011: p.655-668.
• [3]Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res. 2004; 427:S6-S15.
• [4]McIlwraith CW. Current concepts in equine degenerative joint disease. J Am Vet Med Assoc. 1982; 180:239-250.
• [5]McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis. Bone Joint Res. 2012; 1:297-309.
• [6]Balazs EA. The Physical Properties of Synovial Fluid and the Special Role of Hyaluronan Acid. In: Disorders of the Knee. Helfet A, editor. JB Lippincott, Philadelphia; 1982: p.61-74.
• [7]Altman RD. Intra-articular sodium hyaluronate in osteoarthritis of the knee. Semin Arthritis Rheum. 2000; 2:11-8.
• [8]Balazs EA. Viscosupplementation for the treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int. 2004; 12:278-289.
• [9]Frisbie DD, Kawcak CE, McIlwraith CW, Werpy NM. Evaluation of polysulphated glucosaminoglycan or sodium hyaluronan administrated intra-articularly for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res. 2009; 70:203-209.
• [10]Christensen LH, Breiting VB, Aasted A, Jørgensen A, Kebuladze I. Long term effects of polyacrylamide hydrogel in human breast tissue. Plast Reconstr Surg. 2003; 111:1883-89.
• [11]Zarini E, Supino R, Pratesi G, Laccabue D, Tortoreto M, Scanziani E et al.. Biocompatibility and tissue interactions of a new filler material for medical use. Plast Reconstr Surg. 2004; 114:934-42.
• [12]Lloyd AW, Faragher RG, Denyer SP. Ocular biomaterials and implants. Biomaterials. 2001; 22:769-85.
• [13]Fernández-Cossío S, Castaño-Oreja MT. Biocompatibility of two novel dermal fillers: histological evaluation of implants of a hyaluronic acid filler and a polyacrylamide filler. Plast Reconstr Surg. 2006; 117:1789-1796.
• [14]Christensen LH, Nielsen J, Mouritsen L, Sørensen M, Lose G. Tissue integration of polyacrylamide hydrogel: an experimental study of periurethral, perivesical, and mammary gland tissue in the pig. Dermatol Surg. 2008; 34:68-77.
• [15]Lose G, Mouritsen L, Nielsen J. A new bulking agent (polyacrylamide hydrogel) for treating stress urinary incontinence in women. Br J Urol Int. 2006; 98:100-117.
• [16]Tnibar A, Schougaard H, Camitz L, Rasmussen J, Koene M, Jahn W et al.. Efficacy of a Polyacrylamide hydrogel in horses with symptomatic osteoarthritis: An International Multi-Centre prospective study [abstract]. Equine Vet J. 2012; Suppl 42, 44:s16.
• [17]Tnibar A, Schougaard H, Camitz L, Rasmussen J, Koene M, Jahn W et al.. An international multi-centre prospective one year study on the efficacy of an intraarticular polyacrylamide hydrogel in horses with osteoarthritis [abstract]. Veterinary Surgery. 2014; 43(8):s204.
• [18]Tnibar A, Persson A, Jensen HE, Svalastoga E, Westrup U, McEvoy F et al.. Evaluation of a polyacrylamide hydrogel in the treatment of induced osteoarthritis in a goat model: A pilot randomized controlled Study [abstract]. Osteoarthritis and Cartilage. 2014; 22:s477.
• [19]Tnibar A, Schougaard H, Koene M, Christensen LH, Markussen B. A controlled clinical trial on the efficacy of an intra-articular Polyacrylamide Hydrogel in horses with osteoarthritis [abstract]. Veterinary Surgery. 2014; 43(5):s138.
• [20]Janssen I, Koene M, Lischer L. Intraartikuläre Applikation von Polyacrylamid Hydrogel zur Behandlung von Osteoarthritis des Hufgelenkes: Fallserie von 12 Pferden. Pferdheilkunde. 2012; 28:650-656.
• [21]Ross MW. Movement. In: Diagnosis and Management of Lameness in the Horse. Ross MW, Dyson SJ, editors. Elsevier, Saunders, St Louis; 2003: p.72-79.
• [22]Butler JA, Colles CM, Dyson SJ, Kold SE, Poulos PW. Foot, pastern and Fetlock. Carpus. In: Clinical Radiology of the horse. 3rd ed. Butler JA, Colles CM, Dyson SJ, Kold SE, Poulos PW, editors. Wiley-Blackwell, Oxford; 2008: p.53-271.
• [23]van Hoogmoed LM, Snyder JR, Thomas HL, Harmon FA. Retrospective evaluation of equine prepurchase examinations performed 1991–2000. Equine vet J. 2003; 35:375-381.
• [24]Elsaid KA, Fleming BC, Oksendahl HL, Machan JT, Fadale PD, Hulstyn MJ et al.. Decreased lubricin concentrations and markers of joint inflammation in the synovial fluid of patients with anterior cruciate ligament injury. Arthritis Rheum. 2008; 58:1707-15.
• [25]Flannery CR, Zollner R, Corcoran C, Jones AR, Root A, Rivera-Bermúdez MA et al.. Prevention of cartilage degeneration in a rat model of osteoarthritis by intraarticular treatment with recombinant lubricin. Arthritis Rheum. 2009; 60:840-7.
• [26]Jay GD, Elsaid KA, Kelly KA, Anderson SC, Zhang L, Teeple E et al.. Prevention of cartilage degeneration and gait asymmetry by lubricin tribosupplementation in the rat following anterior cruciate ligament transection. Arthritis Rheum. 2012; 64:1162-71.
• [27]Hall MC, Doherty S, Zhang W, Doherty M. Knee joint stiffness and its relationship to severity of radiographic osteoarthritis, pain and self-reported stiffness [abstract]. Osteoarthritis and cartilage. 2014; 22:s92.
• [28]Keegan KG, Dent EV, Wilson DA, Janicek J, Kramer J, Lacarrubba A et al.. Repeatability of subjective evaluation of lameness in horses. Equine Vet J. 2010; 42:92-7.